Literature DB >> 8544149

Depressive disorder due to craniopharyngioma.

S A Spence1, D G Taylor, S R Hirsch.   

Abstract

Secondary causes of depression are legion, and must always be considered in patients presenting with features atypical of primary idiopathic depressive disorder. The case described is that of a middle-aged woman presenting initially with a major depressive disorder who was subsequently found to have a craniopharyngioma, leading to a revised diagnosis of mood disorder due to the tumour. Some features of the presentation might have led to earlier diagnosis had their localizing significance been recognized. Diencephalic lesions should always be considered in patients presenting with the hypersomnic-hyperphagic variant of depressive disorder.

Entities:  

Mesh:

Year:  1995        PMID: 8544149      PMCID: PMC1295388          DOI: 10.1177/014107689508801109

Source DB:  PubMed          Journal:  J R Soc Med        ISSN: 0141-0768            Impact factor:   18.000


  4 in total

1.  Craniopharyngioma in the elderly.

Authors:  R W RUSSELL; J B PENNYBACKER
Journal:  J Neurol Neurosurg Psychiatry       Date:  1961-02       Impact factor: 10.154

2.  Memory disturbances in third ventricle tumours.

Authors:  M WILLIAMS; J PENNYBACKER
Journal:  J Neurol Neurosurg Psychiatry       Date:  1954-05       Impact factor: 10.154

3.  Hyperphagia, rage, and dementia accompanying a ventromedial hypothalamic neoplasm.

Authors:  A G Reeves; F Plum
Journal:  Arch Neurol       Date:  1969-06

4.  Colloid cyst of the third ventricle presenting as psychiatric disorder.

Authors:  F M Burkle; Z J Lipowski
Journal:  Am J Psychiatry       Date:  1978-03       Impact factor: 18.112

  4 in total
  2 in total

Review 1.  Psychiatric aspects of brain tumors: A review.

Authors:  Subramoniam Madhusoodanan; Mark Bryan Ting; Tara Farah; Umran Ugur
Journal:  World J Psychiatry       Date:  2015-09-22

Review 2.  The relationships between depression and brain tumors.

Authors:  N Scott Litofsky; Andrew G Resnick
Journal:  J Neurooncol       Date:  2009-03-05       Impact factor: 4.130

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.